FPI(300203)2024-10-21 10:28Financial Performance - Net profit attributable to shareholders for the first three quarters of 2024 is expected to be between RMB 110 million and RMB 124 million, a significant improvement from a loss of RMB 176.2275 million in the same period last year[1] - Net profit attributable to shareholders for Q3 2024 is projected to be between RMB 67 million and RMB 77 million, compared to a loss of RMB 38.8346 million in Q3 2023[2] - Revenue for the reporting period reached approximately RMB 2.3 billion, a 12% increase year-over-year[4] - Operating cash flow improved significantly to approximately RMB 78 million[4] - Non-recurring gains and losses attributable to the company are estimated at around RMB 50 million, primarily from government subsidies[4] Cost and Expense Management - Gross margin improved due to optimized business and product structures, as well as enhanced contract quality[4] - Sales, management, and R&D expenses as a percentage of revenue and total amount decreased compared to the same period last year[4] Strategic Focus and Product Development - The company focused on developing high-end analytical instruments, scientific instruments, and related products in competitive fields such as clinical and life sciences, "dual-carbon" detection, and semiconductor precision testing[4]